Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company.
As a fully integrated pharmaceutical company, their purpose is to provide affordable and innovative medicines
Dr. Reddy's products are marketed globally, with a focus on India, US, Europe and Russia. Dr. Reddy’s conducts NCE research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation.
The strong portfolio of businesses, geographies and products gives them an edge in an increasingly competitive global market and allows us to provide affordable medication to people across the world, regardless of geographic and socio-economic barriers.
Deep Manufacturing Expertise
The company has 16 world-class manufacturing facilities of which 9 have a long history of regular USFDA inspections. With an annual capacity of nine billion tablets/ capsules a year, dedicated to servicing the more regulated markets, one of their finished dosages facilities is among the largest in Asia. The facilities are designed to respond to a wide range of technologies - oral solids, injectibles, topicals, inhalers, cytotoxic, hormonals and other dosage forms.
Pharma major Dr Reddy's Laboratories Ltd's consolidated net profit grew 57 per cent to Rs 310 crore in the fourth quarter ended March 31, 2011, compared with the year ago period.
Total revenues increased 23 per cent to Rs 2,017 crore (Rs 1,642 crore). Revenues for the full year ended March 31, 2011, were up 6 per cent at Rs 7,467 crore, while profits were up
14 per cent at Rs 1,080 crore.
Dr. Reddy's Laboratories Ltd.
8-2-337, Road No 3,
Banjara Hills, Hyderabad - 500034,
Andhra Pradesh - INDIA